Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Platypus venom could treat diabetes
Platypus
The hormone produced in the gut of the platypus to regulate blood glucose, is also produced in its venom.

Scientists discover longer-lasting form of GLP-1 hormone

A powerful venom secreted by the platypus during breeding season could lead to new treatments for type 2 diabetes in humans, according to new research. 


Scientists at the University of Adelaide and Flinders University were surprised to discover that the hormone produced in the gut of the platypus to regulate blood glucose, is also produced in its venom.

“This is an amazing example of how millions of years of evolution can shape molecules and optimise their function," said lead co-author Professor Frank Grutzner.


"These findings have the potential to inform diabetes treatment, one of our greatest health challenges, although exactly how we can convert this finding into a treatment will need to be the subject of future research."

The hormone, known as glucagon-likepeptide-1 (GLP-1), is secreted in the gut of both humans and animals. Its job is to stimulate the release of insulin to lower glucose in the blood, but GLP-1 typically degrades within minutes.


In people with type 2 diabetes, the short stimulus triggered by GLP-1 is not enough to maintain a proper balance of sugar. As such, a medication that includes a longer lasting form of the hormone is needed to help provide an extended release of insulin.


Reporting their findings in the journal Scientific Reports, the authors describe how the GLP-1 hormone in the platypus has evolved, making it resistant to the rapid degradation seen in humans.


"We've found that GLP-1 is degraded in monotremes by a completely different mechanism,” explained Professor Grutzner.

“Further analysis of the genetics of monotremes reveals that there seems to be a kind of molecular warfare going on between the function of GLP-1, which is produced in the gut but surprisingly also in their venom," he said.

During breeding season, the platypus produces a powerful venom which is used is competition among males for females.


The researchers discovered conflicting functions of GLP-1 in the platypus: in the gut as a regulator of blood glucose, and in venom to fend off other platypus males during breeding season.


“This tug of war between the different functions has resulted in dramatic changes in the GLP-1 system," said co-lead author Professor Briony Forbes.

"The function in venom has most likely triggered the evolution of a stable form of GLP-1 in monotremes. Excitingly, stable GLP-1 molecules are highly desirable as potential type 2 diabetes treatments.”


The team also discovered GLP-1 in the venom of echidnas, and are now looking for a way to convert their discovery into a possible treatment for type 2 diabetes.  

Image (C) Klaus/Wikimeda Commons

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.